Sleep apnea can affect anyone and for several different reasons. Factors could be your hectic lifestyle or old age. Sleep apnea can disrupt your everyday life and lead to serious health consequences. Dr. Avi Weisfogel is a highly reputable doctor who has identified ways to prevent and treat sleep apnea. During his research, he found several different causes of sleep apnea and lack of sleep. He developed programs and therapies that can help patients combat the infection. While researching other diseases, he found that there was a connection between diabetes, stroke and sleep apnea.
Nurturing and caring for the children of tomorrow is a responsibility that everyone shares; nurturing their minds, and bodies so they themselves can push the boundaries of our world. This is just one of the many beliefs of Amicus Therapeutics.
Amicus Therapeutics is global biotechnology company that leads in the innovation of treating rare and orphan diseases. These mainly include diseases that deal lysosomal storage disorders such as Fabry disease and Pompe disease. Epidermolysis Bullosa (EB) is another disease that Amicus Therapeutics is thoroughly invested in. Being at the forefront of treatments for these diseases is the mission Amicus Therapeutics is trying to achieve. Under the leadership of John F. Crowley, who is the Chairman and CEO, Amicus Therapeutics is taking amazing strides towards treatments that could revolutionize the biotech industry. Mr. Crowley has two children of his own who was diagnosed with Pompe disease. This led him on a journey to not only find a treatment for his own children but to give the children of tomorrow a fighting chance against such diseases.
Amicus Therapeutics is currently most known for their drug Migalastat or Galafold. This drug is a long-term treatment option for children who suffer from Fabry disease. But even with this amazing achievement Amicus Therapeutics is still working towards helping children with other diseases as well. They currently have a Proprietary Topical Formulation (SD-101) that is in its phase three of its clinical trials for the disease Epidermolysis Bullosa, as well as a Novel Enzyme Replacement Therapy, Novel ERT for short, for Pompe Disease (ATB200/AT2221).
Not only does Amicus Therapeutics continue their works through their own organization and treatments but through other non-profit organizations as well. Amicus Therapeutics believes in spreading awareness of these diseases as well as providing services, and activities for those in need. From their actions, Amicus Therapeutics have proved that they are committed to improving every aspect of life.
More about Amicus Therapeutics at https://finance.yahoo.com/quote/FOLD?ltr=1